Elafibranor

Each film-coated tablet contains: Elafibranor………………………………80mg.

INDICATION:

LuciElafib is a peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.

DOSAGE AND USE:

The recommended dosage is 80 mg orally once daily with or without food.

STORAGE:

In a dry place and store at 20℃ to 25℃.

WARNING:

Keep medicine out of reach of Children. Do not administer LuciElafib during Pregnancy and Lactation.

PLEASE SEE PACKAGE INSERT